Background: As a marker of left ventricular dysfunction, Pro-B-type natriuretic peptide (proBNP) is a practical tool that facilitates diagnosis, contributes to prognostic evaluations and tracks disease severity. To date, the relationship of proBNP with cardiac function and prognosis of acute coronary syndrome is investigated. Purposes: The aim of this study is to clarify the predictive value of proBNP for the major adverse cardiac event (MACE) in accordance with the types of implanted stent. Methods: This retrospective study included 466 patients (696 lesions) from Nov. 2002 to Jun. 2004, who underwent coronary stent. All patients were divided into two groups: group 1 BMS, group 2 DES. Initial proBNP and the clinical outcomes were analyzed between the groups. Results: 12 months clinical follow-up was available in 89.3%. See the following table. Conclusions: According to the results of our study, proBNP could predict the MACE after coronary intervention with BMS, not with DES. This difference might be related to powerful preventive effect of DES for the MACE, especially in acute myocardial infarction.